PAR22 COST-EFFECTIVENESS OF RITUXIMAB (MABTHERA) COMPARED WITH ABATACEPT (ORENCIA) FOR THE TREATMENT OF MODERATE/SEVERE RHEUMATOID ARTHRITIS (RA) IN THE UNITED KINGDOM
Nov 1, 2007, 00:00 AM
10.1016/S1098-3015(10)64937-6
https://www.valueinhealthjournal.com/article/S1098-3015(10)64937-6/fulltext
Section Title :
Section Order :
96
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)64937-6&doi=10.1016/S1098-3015(10)64937-6